Practice: Infectious Diarrhea: When To Test and When To Treat
Practice: Infectious Diarrhea: When To Test and When To Treat
Practice: Infectious Diarrhea: When To Test and When To Treat
CMAJ Practice
Primer
A
cute gastrointestinal illness is common. mation acquired from thorough history-taking
declared.
An estimated 1.3 episodes per person and physical examination.
occur each year in Canada, which trans- Clinical features that help direct management This article has been peer
reviewed.
lates to more than 40 million incidents at an esti- include characteristics of the stool (e.g., bloody,
mated cost of $3.7 billion annually.1 Acute diar- watery), associated symptoms (e.g., fever, tenes- Correspondence to:
rhea is the second most common reason travellers mus) and, in some instances, the intensity of the Dr. Todd F. Hatchette,
todd.hatchette@cdha
returning from developing countries seek medical vomiting. A detailed description of the clinical .nshealth.ca
attention.2 In most instances, infectious diarrhea features associated with specific pathogens can
CMAJ 2011. DOI:10.1503
is self-limiting and treatment does not depend on be found in recent reviews.4–6 /cmaj.091495
identification of the responsible pathogen. The Additional information that may help in
challenge for front-line clinicians is to recognize deciding whether testing is necessary and what
who requires testing and treatment. testing is required includes underlying comor-
The diagnostic yield of stool cultures is rela- bidities, travel history, ingestion of unfiltered
tively low, estimated to range from 1.5% to water, recent use of antibiotics, recent contact
5.6%, which for example translates to a cost of with a sick individual, dietary history focusing
US$952 to US$1200 per positive sample in the on foods that are at high risk for transmitting
United States.3 Therefore, selective testing has diarrheal illness (raw or undercooked meat,
been used to improve the cost-effectiveness of shellfish, eggs or milk), employment (daycare
testing. When deciding whether testing is war- worker, food handler, health care worker) and
ranted, clinicians need to consider two questions: residence in a closed facility (e.g., long-term care
Will identification of the pathogen influence facility).3–5
patient management, such as treatment or infec- Evidence of volume depletion is important to
tion-control measures? Is identification of the assess the severity of the illness. Reduced skin
causative agent important from a public health turgor and dry mucous membranes may reflect
perspective? This primer is a summary of infor- mild volume depletion. Tachycardia, an orthosta-
mation obtained from recent reviews, clinical tri- tic drop in blood pressure, hypotension, changes
als and guidelines. in mental status, listlessness in children and
weight loss in infants are all suggestive of severe
dehydration.3 Examination of the abdomen may
What factors are important on reveal focal or diffuse tenderness. Rebound ten-
history and examination? derness suggestive of peritoneal inflammation
should warrant further assessment to rule out
Ingestion of many different bacteria, viruses, severe colitis or perforation.
parasites and bacterial toxins can all lead to acute
presentation of vomiting and diarrhea. Infectious Key points
diarrhea can be classified in several ways. One
• Acute infectious diarrhea is a common, usually self-limiting condition
simple approach is to categorize patients into that is underreported to public health authorities.
two groups: those who present with bloody diar- • Testing should be considered when patients present with diarrhea of
rhea and those who present with nonbloody diar- more than one day’s duration associated with bloody stools, fever,
rhea (Table 1).3–5 symptoms of sepsis or evidence of dehydration, recent antibiotic use or
The initial assessment of anyone presenting underlying immunocompromised state, or when identification of the
causative agent is important from a public health perspective.
with infectious diarrhea should focus on severity,
need for hydration and historical clues as to the • Although antibiotics can reduce the duration of symptoms in
nonbloody travellers’ diarrhea, use of antibiotics to treat this otherwise
cause in the patient. The decision to test for a self-limited illness may not justify the risk of antimicrobial resistance in
specific pathogen, notify public health or start the community.
empirical treatment can be influenced by infor-
© 2011 Canadian Medical Association or its licensors CMAJ, February 22, 2011, 183(3) 339
infect-hatchette_Layout 1 02/02/11 10:33 AM Page 340
Practice
Practice
travellers with nonbloody diarrhea and people the combined data from six trials showed that
with bloody diarrhea (Figure 2).3,5,13 diarrhea in patients with travel-associated, non-
The most common causes of community- bloody diarrhea resolved one to two days earlier
acquired, infectious diarrhea are viral and short- on average with antibiotic use; however, the
lived. Conservative management with hydra- incidence of side effects was greater among
tion, with or without loperamide, is the most these patients than among those who were not
appropriate approach in most instances. Al - given antibiotics.16 Despite these data, in an era
though guidelines suggest that antibiotic treat- of increasing rates of antimicrobial resistance,
ment can be considered for patients with fever the small improvement in recovery from an oth-
and moderate or severe disease,3 the benefits erwise self-limited illness may not justify the
need to be weighed against the potential disad- risk of antimicrobial resistance in the com -
vantages of antibiotic use. A meta-analysis of munity. However, if symptoms are severe or
Patient presents
with diarrhea
No Yes History of
antibiotic use in
Assess severity: does Order stool last few weeks?
the patient have any culture for:
of the following? • Salmonella
• Dehydration • Shigella Order assay
• Fever • Campylobacter for C. difficile
• Underlying comorbid • E. coli O157 toxin
illness • Yersinia
Yes
No
Add test for: Add culture Add assay for Add stool
• Norovirus for Vibrio C. difficile examination
• Rotavirus toxin for ova and
• Adenovirus parasites
Figure 1: Algorithm for deciding when testing is required in patients who present with infectious diarrhea.3–5
Note: C. difficile = Clostridium difficile, EIA = enzyme immunoassay.
Practice
worsen, empirical therapy can be considered In patients with a positive culture result, the
(Figure 2). decision to treat depends on the pathogen, the
Empirical treatment should be avoided in length of time from symptom onset, and comor-
patients presenting with bloody stools, because bidities. Documented bacteremia requires antibi-
potential causes include Escherichia coli O157 otic treatment. In Shigella and Campylobacter
or other strains producing Shiga-like toxin. infections, antibiotic treatment is associated with
Although the data analyzed in a recent sys- reduced severity and bacterial shedding.4 How-
temic review of antibiotic use and risk of ever, in Campylobacter infections, a study pub-
hemolytic uremic syndrome in patients with a lished in 1982 showed that antibiotics must be
toxin-producing strain of E. coli O157 were given within four days after symptom onset,21
conflicting, most clinicians recommend against and a recent meta-analysis showed that antibiotic
antibiotic treatment.9,17,18 (Box 1 outlines the treatment shortened the duration of symptoms by
clinical features suggestive of infection with only 1.3 days.22
E. coli O157.19,20) In addition, Shigella infec- Although treatment of Salmonella carries
tions are rarely life-threatening; thus, waiting with it an increased risk of chronic carriage, bac-
for the results of the stool culture in a patient teremia can occur in 2%–4% of patients.4 There-
with bloody stools is reasonable before starting fore, treatment should be considered in individu-
therapy.20 als with a positive culture result and who are at
Figure 2: Algorithm for deciding whether empirical treatment of infectious diarrhea is required.3,5,12 *For nonbloody diarrhea with a his-
tory of travel, antibiotic use only reduces symptoms by 1–2 days and is associated with side effects; such treatment may not be justi-
fied in an era of antimicrobial resistance. †1000 mg of azithromycin can cause nausea. Note: C. difficile = Clostridium difficile, E. coli =
Escherichia coli.
Practice
Practice
14. DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative
return to work.1 Recommendations regarding efficacy of loperamide hydrochloride and bismuth subsalicylate
which pathogens and patients should prompt fol- in the management of acute diarrhea. Am J Med 1990;88:15S-9S.
low-up testing can vary among provinces. As 15. Li ST, Grossman DC, Cummings P. Loperamide therapy for
acute diarrhea in children: systematic review and meta-analysis.
such, clinicians should consult their local public PLoS Med 2007;4:e98.
health officials for further guidance. 16. De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for trav-
ellers’ diarrhea. Cochrane Database Syst Rev 2000;3:CD002242.
17. Panos GZ, Betsi GI, Falagas ME. Systematic review: Are antibi-
References otics detrimental or beneficial for the treatment of patients with
Escherichia coli O157:H7 infection? Aliment Pharmacol Ther
1. Thomas MK, Majowicz SE, Pollari F, et al. Burden of acute gas-
2006;24:731-42.
trointestinal illness in Canada, 1999–2007: interim summary of
18. Bavaro MF. Escherichia coli O157: What every internist and
NSAGI activities. Can Commun Dis Rep 2008;34:8-15.
gastroenterologist should know. Curr Gastroenterol Rep 2009;
2. Freedman DO, Weld LH, Kozarsky PE, et al. GeoSentinel Sur-
11:301-6.
veillance Network. Spectrum of disease and relation to place of
19. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing
exposure among ill returned travelers. N Engl J Med 2006;354:
Escherichia coli and haemolytic uraemic syndrome. Lancet
119-30.
2005;365:1073-86.
3. Guerrant RL, Van Gilder T, Steiner TS, et al. Infectious Dis-
20. Holtz LR, Neill MA, Tarr PI. Acute bloody diarrhea: a medical
eases Society of America. Practice guidelines for the manage-
emergency for patients of all ages. Gastroenterology 2009;136:
ment of infectious diarrhea. Clin Infect Dis 2001;32:331-51.
1887-98.
4. Thielman NM, Guerrant RL. Acute infectious diarrhea. N Engl J
21. Anders BJ, Lauer BA, Paisley JW, et al. Double-blind placebo
Med 2004;350:38-47.
controlled trial of erythromycin for treatment of Campylobacter
5. DuPont HL. Clinical practice. Bacterial diarrhea. N Engl J Med
enteritis. Lancet 1982;1:131-2.
2009;361:1560-9.
22. Ternhag A, Asikainen T, Giesecke J, et al. A meta-analysis on
6. Davies AP, Chalmers RM. Cryptosporidiosis. BMJ 2009;339:
the effects of antibiotic treatment on duration of symptoms
b4168.
caused by infection with Campylobacter species. Clin Infect Dis
7. Oral rehydration salts: production of the new ORS. Geneva
2007;44:696-700.
(Switzerland): World Health Organization; 2006. Available:
23. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium
http://whqlibdoc.who.int/hq/2006/WHO_FCH_CAH_06.1.pdf
difficile infection. Clin Infect Dis 2008;46:S32-42.
(accessed 2010 Dec. 15).
24. Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shed-
8. Rehydration Project. Oral rehydration solutions made at home.
ding after experimental human infection. Emerg Infect Dis 2008;
The Mother and Child Health and Education Trust; 2010. Avail-
14:1553-7.
able: http://rehydrate.org/solutions/homemade.htm (accessed
25. Stirling R, Aramini J, Ellis A, et al. Waterborne cryptosporidio-
2009 Nov. 26).
sis outbreak, North Battleford, Saskatchewan, Spring 2001. Can
9. Al-Abri SS, Beeching NJ, Nye FJ. Traveller’s diarrhoea. Lancet
Commun Dis Rep 2001;27:185-92.
Infect Dis 2005;5:349-60.
10. Atia AN, Buchman AL. Oral rehydration solutions in non-
cholera diarrhea: a review. Am J Gastroenterol 2009;104:2596- Affiliations: From the Division of Microbiology, Depart-
604. ment of Pathology and Laboratory Medicine (Hatchette), and
11. Harris C, Wilkinson F, Mazza D, et al. Health for Kids Guide-
the Division of Gastroenterology, Department of Medicine
line Development Group. Evidence based guideline for the man-
agement of diarrhoea with or without vomiting in children. Aust (Farina), Capital District Health Authority, Halifax, NS; and
Fam Physician 2008;37:22-9. the Departments of Pathology (Hatchette) and Medicine
12. Huang DB, Awasthi M, Le BM, et al. The role of diet in the (Farina), Dalhousie University, Halifax, NS
treatment of travelers’ diarrhea: a pilot study. Clin Infect Dis
2004;39:468-71. Contributors: Both authors contributed equally to the writ-
13. Hill DR, Ryan ET. Management of traveler’s diarrhoea. BMJ ing and revision of the manuscript, and both approved the
2008;337:a1746. final version submitted for publication.